PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.78%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-4.70%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-40.44%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-35.51%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
0.99%
D&A change of 0.99% while TRAW maintains D&A. Bruce Berkowitz would investigate efficiency.
41.12%
Similar EBITDA growth to TRAW's 38.18%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
40.44%
Similar operating income growth to TRAW's 38.17%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
-17.42%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
42.50%
Pre-tax income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42.50%
Net income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
40.54%
EPS growth while TRAW declines. John Neff would investigate advantages.
40.54%
Diluted EPS growth while TRAW declines. John Neff would investigate advantages.
0.40%
Share count reduction exceeding 1.5x TRAW's 61.48%. David Dodd would verify capital allocation.
0.40%
Diluted share reduction exceeding 1.5x TRAW's 61.48%. David Dodd would verify capital allocation.